The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas
Open Access
- 16 June 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 207 (2) , 612-618
Abstract
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed. Magrolimab, a CD47-blocking antibody, disrupts CD47:SIRPα-mediated antiphagocytic signalling. When combined with a prophagocytic signal from an anti-CD20 antibody rituximab, it has shown activity in relapsed or refractory FL and MZL. In this phase 1 study, adding the BCL2-inhibitor venetoclax to magrolimab and the anti-CD20 antibody obinutuzumab resulted in complete responses in 6 of 10 (60%) evaluable patients with FL, MZL or CLL. Notably, we did not observe increased risk of infections previously reported from studies of magrolimab in acute myeloid leukaemia and higher risk myelodysplastic syndromes.Keywords
Funding Information
- Clinical Center
This publication has 19 references indexed in Scilit:
- Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemiaNature Reviews Clinical Oncology, 2024
- Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?Oncology and Therapy, 2024
- Frequency and Outcomes of Obinutuzumab-Induced ThrombocytopeniaBlood, 2023
- Obinutuzumab‐induced acute thrombocytopenia: Report of two cases and review of literatureBritish Journal of Haematology, 2023
- The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and VenetoclaxBlood, 2018
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s LymphomaNew England Journal of Medicine, 2018
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2016
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implicationsCurrent Opinion in Immunology, 2012
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemiaNature Medicine, 1999